WVU Cancer Institute offering groundbreaking treatment for gastroenteropancreatic neuroendocrine tumors

WVU Cancer Institute offering groundbreaking treatment for gastroenteropancreatic neuroendocrine tumors

MORGANTOWN, W.Va. – The WVU Cancer Institute is participating in the implementation of a new drug therapy for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a type of tumor that can form in the pancreas or in other parts of the gastrointestinal tract, including the stomach, small intestine, colon, rectum, and appendix. These life-threatening tumors can spread to other organs, such as the liver.

Lutetium Lu 177 dotatate, known by the brand name Lutathera®, is a form of radiation therapy that slows the progress of these tumors. It is delivered intravenously in four doses administered over eight weeks and is indicated for adult patients with low- to mid-grade somatostatin receptor-positive GEP-NETs.

“This new therapy is a way to provide treatment to our patients without the side effects of previous forms of treatment,” Shalu Pahuja, M.D., medical oncologist at the WVU Cancer Institute, said. “This drug slows the progress of the tumor in order to give them more time to spend with their family and loved ones.”

The use of this treatment of GEP-NETs was approved by the U.S. Food and Drug Administration in January. This is the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of GEP-NETs.

“This treatment can greatly improve the quality of life for patient with GEP-NET tumors,” Gary Marano, M.D., medical director of PET/CT at WVU Medicine J.W. Ruby Memorial Hospital, said. “We are the only hospital in the state approved to use Lutathera, so this allows us to have a significant impact in the lives of these patients.”

For more information on the WVU Cancer Institute, visit www.wvumedicine.org/cancer.

For more information: Heather Sammons, Communications Specialist, 304-285-7256
  • WVU Heart and Vascular Institute physicians use ECMO to address complicated airway

    WVU Heart and Vascular Institute physicians use ECMO to address complicated airway

    Physicians at the WVU Heart and Vascular Institute have used extracorporeal membrane oxygenation, or ECMO, to provide oxygen to a patient while she underwent rigid bronchoscopy to relieve complete airway obstruction. This is the first time ECMO has been used in the state to address a complicated airway.

    Read More

  • Esophageal diseases: New minimally invasive treatments

    Esophageal diseases: New minimally invasive treatments

    The WVU Heart and Vascular Institute’s Center for Esophageal Disease is here to provide you with the most cutting-edge therapies in the state of West Virginia for diseases of the esophagus. Our expert diagnosis and treatment methods are available to help you with a variety of esophageal conditions. We examine the issue closely with highly-advanced imaging and diagnostics, and our minimally invasive and robotic surgery options will have you back to your normal routine sooner than most procedures.

    Read More

  • WVU Medicine Urgent Care in McHenry receives accreditation from the Urgent Care Association

    WVU Medicine Urgent Care in McHenry receives accreditation from the Urgent Care Association

    The WVU Medicine Urgent Care in McHenry has received the Accredited Urgent Care designation, the highest level of distinction for urgent care centers, from the Urgent Care Association.  

    Read More